Similar articles for PMID: 14986280

Year	Number of Results
1997	1
1998	5
1999	2
2000	2
2001	5
2002	3
2003	10
2004	11
2005	6
2006	5
2007	8
2008	17
2009	10
2010	4
2011	7
2012	8
2013	9
2014	3
2015	4
2016	2
2017	3
2020	1
2024	0

1

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.

Sulkowski MS. Sulkowski MS. Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S90-7. doi: 10.1086/381444. Clin Infect Dis. 2004. PMID: 14986280

2

[Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].

Rivero A, Camacho A, Pérez-Camacho I, Torre-Cisneros J. Rivero A, et al. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:45-8. doi: 10.1016/S0213-005X(08)76620-5. Enferm Infecc Microbiol Clin. 2008. PMID: 20116617 Review. Spanish.

3

Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.

Sulkowski MS. Sulkowski MS. Semin Liver Dis. 2003 May;23(2):183-94. doi: 10.1055/s-2003-39949. Semin Liver Dis. 2003. PMID: 12800071 Review.

4

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E; SWAN Study Group. Gatell J, et al. Clin Infect Dis. 2007 Jun 1;44(11):1484-92. doi: 10.1086/517497. Epub 2007 Apr 25. Clin Infect Dis. 2007. PMID: 17479947 Clinical Trial.

5

Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.

Nguyen ST, Eaton SA, Bain AM, Rahman AP, Payne KD, Bedimo R, Herrington JD, Maclayton DO, Rodriguez-Barradas MC, Busti AJ. Nguyen ST, et al. Pharmacotherapy. 2008 Mar;28(3):323-30. doi: 10.1592/phco.28.3.323. Pharmacotherapy. 2008. PMID: 18294112

6

[Efficacy of atazanavir in simplification regimens].

Zamora L, Gatell JM. Zamora L, et al. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:14-21. doi: 10.1016/S0213-005X(08)76615-1. Enferm Infecc Microbiol Clin. 2008. PMID: 20116612 Review. Spanish.

7

Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.

East J, Blanton LS. East J, et al. Antimicrob Agents Chemother. 2012 Feb;56(2):1081-3. doi: 10.1128/AAC.05806-11. Epub 2011 Nov 28. Antimicrob Agents Chemother. 2012. PMID: 22123706 Free PMC article.

8

Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.

de Mendoza C, Valer L, Ribera E, Barreiro P, Martín-Carbonero L, Ramirez G, Soriano V. de Mendoza C, et al. HIV Clin Trials. 2006 Jul-Aug;7(4):163-71. doi: 10.1310/hct0704-163. HIV Clin Trials. 2006. PMID: 17065028

9

[Clinical utility of atazanavir].

Ribera Pascuet E, Curran A. Ribera Pascuet E, et al. Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 17:55-67. doi: 10.1016/S0213-005X(08)76622-9. Enferm Infecc Microbiol Clin. 2008. PMID: 20116619 Review. Spanish.

10

Knee avascular necrosis in HIV patient.

Declet VR, Salas AS. Declet VR, et al. Bol Asoc Med P R. 2015 Apr-Jun;107(2):24-6. Bol Asoc Med P R. 2015. PMID: 26434077 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

120 results

Results by year